1000068-24-5 Usage
Uses
Used in Organic Synthesis:
1H-Indole-1-carboxylic acid, 2-borono-7-chloro-, 1-(1,1-dimethylethyl) ester is used as a reagent in organic synthesis for its unique reactivity due to the boron and chlorine groups, allowing for selective modifications of other chemical structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Indole-1-carboxylic acid, 2-borono-7-chloro-, 1-(1,1-dimethylethyl) ester is utilized as a key intermediate in the synthesis of indole-containing compounds, which are often found in biologically active molecules with potential therapeutic applications.
Used in Drug Discovery and Development:
1H-Indole-1-carboxylic acid, 2-borono-7-chloro-, 1-(1,1-dimethylethyl) ester is employed as a building block in drug discovery and development, where its enhanced stability and solubility, due to the tert-butyl ester group, facilitate the creation of diverse molecular architectures with potential medicinal properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1000068-24-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,0,6 and 8 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1000068-24:
(9*1)+(8*0)+(7*0)+(6*0)+(5*0)+(4*6)+(3*8)+(2*2)+(1*4)=65
65 % 10 = 5
So 1000068-24-5 is a valid CAS Registry Number.
1000068-24-5Relevant academic research and scientific papers
2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
-
Page/Page column 49-50, (2008/06/13)
The present invention is directed to 2-phenyl-indole compounds (A), their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not li
PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS
-
Page/Page column 150, (2008/06/13)
The present invention relates to compounds of the general formula (I) wherein X, Y, Z, A, Ar, R1, R2, R3, and R4 are as defined herein, which compounds are inhibitors of MNK2 and MNK1. The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds, and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of disorders related to undesired activity of MNK1 and/or MNK2 kinases.
